Crossmark

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Crossref DOI link: https://doi.org/10.1186/s13058-018-1092-x

Published Online: 2019-01-22

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Camilio, Ketil A. https://orcid.org/0000-0002-7440-4265
Wang, Meng-Yu

Mauseth, Brynjar

Waagene, Stein

Kvalheim, Gunnar

Rekdal, Øystein

Sveinbjørnsson, Baldur

Mælandsmo, Gunhild M.
Funding

Funding for this research was provided by:

Lytix Biopharma AS
License Information

Text and Data Mining valid from 2019-01-22
More Information

Article History

Received: 3 June 2018

Accepted: 20 December 2018

First Online: 22 January 2019

Ethics approval

: All procedures performed were approved by the Experimental Animal Board under the Ministry of Agriculture of Norway and in compliance with The European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes. The manuscript does not contain any individual person’s data.

: All authors approved of the manuscript and consented to its publication.

: Øystein Rekdal, Baldur Sveinbjørnsson and Ketil André Camilio are employees and shareholders in Lytix Biopharma AS. Brynjar Mauseth in an employee in Lytix Biopharma AS. The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.